IL-17A and its receptors are expressed across different tumor types and contribute to a protumor niche via different pathways, such as promoting tumor chemoresistance and proliferation through extracellular signal-regulated kinase 1/2 (ERK1/2) in breast cancer [8]. Here, MAPK3 is linked to breast cancer.